Nakagawa R

References (4)

Title : Associated factors of diabetic retinopathy by artificial intelligence evaluation of fundus images in Japan - Komatsu_2023_Sci.Rep_13_19742
Author(s) : Komatsu K , Sano K , Fukai K , Nakagawa R , Nakagawa T , Tatemichi M , Nakano T
Ref : Sci Rep , 13 :19742 , 2023
Abstract : This cross-sectional study aimed to investigate the promoting and inhibitory factors of diabetic retinopathy (DR) according to diabetes mellitus (DM) stage using standardized evaluation of fundus images by artificial intelligence (AI). A total of 30,167 participants underwent blood and fundus examinations at a health screening facility in Japan (2015-2016). Fundus photographs were screened by the AI software, RetCAD and DR scores (DRSs) were quantified. The presence of DR was determined by setting two cut-off values prioritizing sensitivity or specificity. DM was defined as four stages (no DM: DM0; advanced DM: DM3) based on treatment history and hemoglobin A1c (HbA1c) levels. Associated factors of DR were identified using logistic regression analysis. For cutoff values, multivariate analysis revealed age, sex, systolic blood pressure (SBP), smoking, urinary protein, and HbA1c level as positively associated with the risk of DR among all DM stages. In addition to glycemic control, SBP and Fibrosis-4 index might act as promoting factors for DR at all or an earlier DM stage. T-Bil, cholinesterase, and T-cho level might be protective factors at an advanced DM stage.
ESTHER : Komatsu_2023_Sci.Rep_13_19742
PubMedSearch : Komatsu_2023_Sci.Rep_13_19742
PubMedID: 37957353

Title : Shark genomes provide insights into elasmobranch evolution and the origin of vertebrates - Hara_2018_Nat.Ecol.Evol_2_1761
Author(s) : Hara Y , Yamaguchi K , Onimaru K , Kadota M , Koyanagi M , Keeley SD , Tatsumi K , Tanaka K , Motone F , Kageyama Y , Nozu R , Adachi N , Nishimura O , Nakagawa R , Tanegashima C , Kiyatake I , Matsumoto R , Murakumo K , Nishida K , Terakita A , Kuratani S , Sato K , Hyodo S , Kuraku S
Ref : Nat Ecol Evol , 2 :1761 , 2018
Abstract : Modern cartilaginous fishes are divided into elasmobranchs (sharks, rays and skates) and chimaeras, and the lack of established whole-genome sequences for the former has prevented our understanding of early vertebrate evolution and the unique phenotypes of elasmobranchs. Here we present de novo whole-genome assemblies of brownbanded bamboo shark and cloudy catshark and an improved assembly of the whale shark genome. These relatively large genomes (3.8-6.7 Gbp) contain sparse distributions of coding genes and regulatory elements and exhibit reduced molecular evolutionary rates. Our thorough genome annotation revealed Hox C genes previously hypothesized to have been lost, as well as distinct gene repertories of opsins and olfactory receptors that would be associated with adaptation to unique underwater niches. We also show the early establishment of the genetic machinery governing mammalian homoeostasis and reproduction at the jawed vertebrate ancestor. This study, supported by genomic, transcriptomic and epigenomic resources, provides a foundation for the comprehensive, molecular exploration of phenotypes unique to sharks and insights into the evolutionary origins of vertebrates.
ESTHER : Hara_2018_Nat.Ecol.Evol_2_1761
PubMedSearch : Hara_2018_Nat.Ecol.Evol_2_1761
PubMedID: 30297745
Gene_locus related to this paper: scyto-a0a401nql2 , chipu-a0a401shd8 , chipu-a0a401rzt4 , scyto-a0a401q2n8 , scyto-a0a401nqq7 , chipu-a0a401s2p9 , scyto-a0a401q2m6 , chipu-a0a401rz56

Title : Long-term effect of galantamine on cognitive function in patients with Alzheimer's disease versus a simulated disease trajectory: an observational study in the clinical setting - Nakagawa_2017_Neuropsychiatr.Dis.Treat_13_1115
Author(s) : Nakagawa R , Ohnishi T , Kobayashi H , Yamaoka T , Yajima T , Tanimura A , Kato T , Yoshizawa K
Ref : Neuropsychiatr Dis Treat , 13 :1115 , 2017
Abstract : BACKGROUND: Long-term maintenance of cognitive function is an important goal of treatment for Alzheimer's disease (AD), but evidence about the long-term efficacy of cholinesterase inhibitors is sparse. To evaluate the long-term efficacy and safety of galantamine for AD in routine clinical practice, we conducted a 72-week post-marketing surveillance study. The effect of galantamine on cognitive function was estimated in comparison with a simulated disease trajectory. PATIENTS AND
METHODS: Patients with mild-to-moderate AD received flexible dosing of galantamine (16-24 mg/day) during this study. Cognitive function was assessed by the mini mental state examination (MMSE) and the clinical status was determined by the Clinical Global Impression-Improvement (CGI-I). Changes of the MMSE score without treatment were estimated in each patient using Mendiondo's model. Generalized linear mixed model analysis was performed to compare the simulated MMSE scores with the actual scores.
RESULTS: Of the 661 patients who were enrolled, 642 were evaluable for safety and 554 were assessed for efficacy. The discontinuation rate was 46.73%. Cognitive decline indicated by the mean change of actual MMSE scores was significantly smaller than the simulated decline. Individual analysis demonstrated that >70% of patients had better actual MMSE scores than their simulated scores. Significant improvement of CGI-I was also observed during the observation period. Adverse events occurred in 28.5% of patients and were serious in 8.41%. The reported events generally corresponded with the safety profile of galantamine in previous studies. CONCLUSION: These findings support the long-term efficacy of galantamine for maintaining cognitive function and the clinical state in AD patients. Treatment with galantamine was generally safe. Importantly, this study revealed that galantamine improved cognitive function above the predicted level in >70% of the patients.
ESTHER : Nakagawa_2017_Neuropsychiatr.Dis.Treat_13_1115
PubMedSearch : Nakagawa_2017_Neuropsychiatr.Dis.Treat_13_1115
PubMedID: 28458553

Title : The comparative efficacy and safety of cholinesterase inhibitors in patients with mild-to-moderate Alzheimer's disease: a Bayesian network meta-analysis - Kobayashi_2016_Int.J.Geriatr.Psychiatry_31_892
Author(s) : Kobayashi H , Ohnishi T , Nakagawa R , Yoshizawa K
Ref : Int J Geriatr Psychiatry , 31 :892 , 2016
Abstract : BACKGROUND: Comparative evidence for efficacy and safety of second-generation cholinesterase inhibitors (ChEIs) is still sparse. OBJECTIVES: The purpose of this research is to compare three ChEIs, donepezil, galantamine and rivastigmine, in patients with mild-to-moderate Alzheimer's disease (AD).
METHODS: We conducted a systematic review for published articles and included randomised, double-blind, placebo-controlled trials and head-to-head randomised trials evaluating the efficacy and safety of ChEIs in patients with AD. We examined Alzheimer's Disease Assessment Scale, cognitive subscale (ADAS-Cog), Neuropsychiatric Inventory (NPI), Clinician's Interview-Based Impression of Change plus caregiver's input (CIBIC+) and Clinical Global Impression of Change (CGIC) as efficacy endpoints. Withdrawals due to adverse events and number of patients experiencing nausea, vomiting, diarrhoea and dizziness were examined as safety profiles. Network meta-analyses were sequentially performed for efficacy and safety outcomes based on drug/dose treatment conditions.
RESULTS: Among the 21 trials included, network meta-analysis showed that all treatments were significantly more efficacious than placebo in cognition measured by ADAS-Cog. All treatments except galantamine were significantly more efficacious than placebo in global change in CIBIC+ or CGIC. Across all conditions, no significant efficacy was observed in neuropsychiatric symptoms measured by NPI. Derived hierarchies in the efficacy of treatment conditions were variables across efficacy and safety.
CONCLUSIONS: Our analysis is the first attempt to incorporate available direct and indirect evidence. The results suggest that ChEIs should have significant efficacy for cognition and global change assessment, but the efficacy on neuropsychiatric symptoms is questionable in patients with mild-to-moderate AD.
ESTHER : Kobayashi_2016_Int.J.Geriatr.Psychiatry_31_892
PubMedSearch : Kobayashi_2016_Int.J.Geriatr.Psychiatry_31_892
PubMedID: 26680338